1. CV Outcomes and Adherence With GLP-1 RAs

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Diabetes and CV Disease

5. EXSCEL CVOT Exenatide Once-Weekly

6. EXSCEL Once-Weekly Exenatide Results

7. Post-Hoc Analysis of EXSCEL

8. SUSTAIN 6 Once-Weekly Semaglutide Results

9. LEADER Once-Daily Liraglutide

10. Clinical Application of Results From LEADER

11. Clinical Application of Results From EXSCEL

12. ELIXA Once-Daily Lixisenatide

13. HARMONY Once-Weekly Albiglutide

14. ITCA-650 Implantable Exenatide

15. Adherence and Persistence

16. Manage Patient Expectations

17. Impact of Delivery Device on Patient Acceptance and Adherence

18. Consider Patient Preferences

19. 2018 ADA/EASD Consensus Report GLP-1 Receptor Agonists With Proven CV Benefit

20. REWIND Once-Weekly Dulaglutide

21. Majority of People With T2D Have CV Disease

22. Primary Prevention

23. GLP-1 RAs and SGLT2 Inhibitors Reduce CV Outcomes

24. Concluding Remarks

25. Abbreviations